Orforglipron Phase 3: Oral Non-Peptide GLP-1 Drug Achieves 7.9% Weight Loss in Diabetic Obesity | Research

The takeaway

Oral orforglipron 36 mg reduced body weight by 7.9% and HbA1c by 1.4% vs placebo over 40 weeks in obese T2D patients, with 66% achieving ≥5% weight loss in the phase 3 ATTAIN-2 trial.

Oral pill, 7.9% weight loss
The first non-peptide oral GLP-1 drug achieved meaningful weight loss in a phase 3 trial — a pill instead of an injection

What the researchers found

Orforglipron 36 mg: -7.9% body weight, -1.4% HbA1c at 40 weeks; 66% achieved ≥5% weight loss; most common AEs: nausea, diarrhea, vomiting; oral non-peptide GLP-1 RA; phase 3 ATTAIN-2 trial.

Why it matters

The first non-peptide oral GLP-1 drug achieving meaningful weight loss in a phase 3 trial could make GLP-1 therapy accessible to many more patients who avoid injections.

How the study worked

Phase 3, randomized, double-blind, placebo-controlled trial (ATTAIN-2) in 1,439 adults with obesity and T2D, comparing oral orforglipron (multiple doses) to placebo over 40 weeks.

What this study cannot tell us

40-week duration. Weight loss less than injectable semaglutide at comparable timepoints. T2D-specific results; non-diabetic data separate.

How to read the evidence

Phase 3 RCT — pivotal trial quality. Definitive for approval pathway.

When this study was published

Published in 2025, ATTAIN-2 trial.

The bigger picture

Orforglipron represents the future of GLP-1 therapy: a daily pill replacing weekly injections, potentially reaching tens of millions more patients.

Questions still open

Will orforglipron achieve injectable-level weight loss with longer treatment?
How does patient preference for oral vs injectable affect real-world adherence?
Will the FDA approve orforglipron based on these results?

Common questions

Is there a GLP-1 pill that works like Ozempic?

Orforglipron is a daily pill that activates the same GLP-1 receptor as Ozempic but is not a peptide — it's a small molecule. In this phase 3 trial, 36 mg produced 7.9% weight loss and 1.4% HbA1c reduction.

How does the pill compare to injections?

Weight loss (7.9% at 40 weeks) is somewhat less than injectable semaglutide, but the convenience of a daily pill could improve adherence. Longer treatment may produce greater weight loss.

Read the original research

Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.

Lancet (London, England), 406(10522), 2927-2944

View on PubMed ↗Publisher’s paper ↗

Citation

Horn, Deborah B; Ryan, Donna H; Kis, Sanja Giljanovic; Alves, Breno; Mu, Yiming; Kim, Sin Gon; Aberle, Jens; Bain, Stephen C; Allen, Sheryl; Sarker, Elizabeth; Wu, Qiwei; Stefanski, Adam; Jouravskaya, Irina. (2026). Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.. Lancet (London, England), 406(10522), 2927-2944. https://doi.org/10.1016/S0140-6736(25)02165-8